Hepato-pancreatic-biliary

Key personnel

  • Chair - Mr Satvinder Mudan, consultant surgeon and senior lecturer in surgery, The Royal Marsden Hospital NHS Foundation Trust  
  • Clinical Board Lead - Dr Kate Haire, consultant in public health medicine, LCA
  • Project manager - Felicity Surridge, LCA

Introduction to the pathway group

The hepato-pancreatic-biliary (HPB) cancer pathway group met for the first time in July 2013. The group set out its aims to improve patient access, experience and outcomes for HPB cancer patients within south and west London. The membership of the group brings together specialist expertise from secondary and tertiary care as well as incorporating future involvement of primary care representatives, patients and users of the services to enable development of high quality patient centred care.

The HPB cancer pathway group supports the aims and objectives of the London Cancer Alliance in providing world class cancer services across south and west London. It aims to improve cancer patients' experience and outcomes through delivering excellence in clinical care, research, innovation and education with particular emphasis on earlier diagnosis for HPB cancers.

Objectives

  • Draw on the highest levels of expertise in its decision making.
  • Review evidence and current performance of pathways within the LCA with regard to outcomes, Model of Care recommendations and best practice.
  • Develop improvement plans and make recommendations for improvement to the LCA Clinical Board.
  • Undertake a baseline audit of the performance of each organisation against delivery of the relevant Model of Care recommendations. The audit will include review against the Model of Care co-dependency framework
  • Agree and establish current best practice, and develop an exemplar best practice pathway.
  • Be compliant with peer review requirements.
  • Existing guidelines for each cancer network within the LCA should be merged to produce a single document used across the LCA. If these do not already exist, the pathway group should produce a new set of guidelines for the LCA on its specific tumour site or pathway.
  • Ensure the appropriate level of engagement with patients, primary care and other key stakeholders, such as public health, ensuring bi-annual stakeholder events.

Outcomes

  • Improve early diagnosis and detection by exploring the possibility of adopting successful screening programmes taken up in other areas of the UK. 
  • Develop strong links with cross-cutting palliative care group to improve patient experience.
  • Improve communication between tertiary treating centres and secondary care to enable more robust referral pathways and comprehensive local follow up.
  • Benchmarking LCA services against international comparators to ensure outcomes for HPB cancer patients remain among the best in the world.
  • Respond to the recommendations in the Model of Care which sets out a minimum caseload for specialist MDTs, requirement for essential collocation of co-dependent services and effective surveillance programmes for high risk patients.
  • Improve HPB cancer patient experience and outcomes through delivering excellence in research, innovation and education.
  • To improve care and ensure equitable access to specialists, GPs, hospitals and healthcare professionals thus improving the outcomes of the population of London.

 

 
Close ×